๐Ÿ”ฌDeep Research

ANVS โ€” Annovis Bio Inc ยท catalysts, narrative & risks

ยท19 sourcesANVS forecast โ†’

Company Snapshot

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern/Berwyn, Pennsylvania, developing the investigational once-daily oral therapy buntanetap (announced as formerly "posiphen" [1], [2]) for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). It is not part of a major headline index [5]. Below is a point-in-time review as of 2026-10-04; it is descriptive, not investment advice.

Recent Catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’